5JA1.F · Sprint Bioscience AB (publ)
-
-
| Industry | Biotechnology |
|---|---|
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | SE0006343745 |
| Sector | Healthcare |
| Market Cap | 3M |
|---|---|
| Beta | -0.07 |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
ABOUT
Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Learn More